Bos Sci names J&J exec as new president, future CEO
Michael Mahoney, worldwide chair of the medical device and diagnostics group for Johnson & Johnson, will become president of Boston Scientific as of Oct. 17, according to a statement from the company. Mahoney is expected to become CEO by Nov. 1, 2012, as well.
The transition period is being implemented to meet post-employment obligations with Johnson & Johnson. Ray Elliot, current president and CEO of Boston Scientific, will step down on Oct. 17, at which time Hank Kucheman, current executive vice president and group president of Cardiology, Rhythm and Vascular Group, will serve as interim CEO for Boston Scientific.
Mahoney served as worldwide chair, Medical Device and Diagnostics Group for Johnson & Johnson since January 2011, prior to which he served as worldwide company group chair of the DePuy franchise from 2007 to 2010, according to the release. Mahoney served as CEO of Global Health Exchange from 2001 to 2006 and has garnered a combined total of 22 years in the healthcare industry.
As president of Boston Scientific, Mahoney will focus on oversight of cardiac rhythm management and endoscopy, as well as other corporate functions. In 2012, he will become responsible for neuromodulation.
The transition period is being implemented to meet post-employment obligations with Johnson & Johnson. Ray Elliot, current president and CEO of Boston Scientific, will step down on Oct. 17, at which time Hank Kucheman, current executive vice president and group president of Cardiology, Rhythm and Vascular Group, will serve as interim CEO for Boston Scientific.
Mahoney served as worldwide chair, Medical Device and Diagnostics Group for Johnson & Johnson since January 2011, prior to which he served as worldwide company group chair of the DePuy franchise from 2007 to 2010, according to the release. Mahoney served as CEO of Global Health Exchange from 2001 to 2006 and has garnered a combined total of 22 years in the healthcare industry.
As president of Boston Scientific, Mahoney will focus on oversight of cardiac rhythm management and endoscopy, as well as other corporate functions. In 2012, he will become responsible for neuromodulation.